Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027

Avalo Therapeutics, Inc.

AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.
IND submission for AVTX-010 expected in the first half of 2027.
Building on abdakibart Phase 2 LOTUS data and the IL-1β pathway conviction.
CEO cites less frequent dosing as key driver for physician and patient preference.
Follows transformational financing completed in May 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.